China's Pharmaceutical Industry 15th Five-Year Plan, Reported 18 September 2026, Lists Quantum Computing for Drug R&D; the 2021 Plan Did Not
Quentir Medicine Monitor
Evidence-based insights for quantum medicine.
On 18 September 2026 Chinese business media reported that the Ministry of Industry and Information Technology and nine other central departments had issued a five-year plan for the pharmaceutical industry that lists quantum computing among the technologies the state wants applied to drug research. The predecessor plan of December 2021 listed artificial intelligence, cloud computing and big data for the same job, and the word quantum did not appear in its published text.
The underlying document, which this Monitor knows through the reports of it rather than from the notice itself, is the 15th Five-Year Plan for the pharmaceutical industry, filed as MIIT joint planning document 2026 number 210 and covering 2026 to 2030. In its passage on frontier technologies, as quoted by the business press, it asks industry, universities, research institutes and hospitals to speed up the use of artificial intelligence, quantum computing, supercomputing and computational medicine in drug research and development. The same plan sets a target that Chinese first-in-class drugs make up at least 25 percent of the global total by 2030.
A planning document is a statement of intent, not a result. For a reader who buys for a hospital or runs a pharmaceutical research group in Europe, its value lies in what it tells you about where Chinese public money, procurement and regulatory attention will go for the rest of the decade, and in the gap between the plan's language and the evidence a physicist in Shanghai asked the same industry to produce a week earlier.
The ten signatories are the Ministry of Industry and Information Technology, the National Development and Reform Commission, the Ministry of Natural Resources, the Ministry of Agriculture and Rural Affairs, the Ministry of Commerce, the National Health Commission, the Ministry of Emergency Management, the National Healthcare Security Administration, the National Administration of Traditional Chinese Medicine and the National Medical Products Administration.